

ERRATUM

Redigueri CF, Porta V, Nunes DSG, Nunes TM, Junginger HE, Kopp S, Midha KK, Shah VP, Stavchansky S, Dressman JB, Barends DM. 2011. Biowaiver Monographs for Immediate-Release Solid Oral Dosage Forms: Metronidazole. *J Pharm Sci* 100:1618–1627.

CAMILA F. REDIGUIERI,¹ VALENTINA PORTA,² DIANA S. G. NUNES,¹ TAINA M. NUNES,¹ HANS E. JUNGINGER,³ SABINE KOPP,⁴ KAMAL K. MIDHA,⁵ VINOD P. SHAH,⁶ SALOMON STAVCHANSKY,⁷ JENNIFER B. DRESSMAN,⁸ DIRK M. BARENDs⁹

¹Division of Bioequivalence, Brazilian Health Surveillance Agency (ANVISA), Brasilia, Brazil

²Faculty of Pharmaceutical Sciences, University of Sao Paulo, Brazil

³Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand

⁴World Health Organization, Geneva, Switzerland

⁵University of Saskatchewan, Saskatoon, Saskatchewan, Canada

⁶International Pharmaceutical Federation (FIP), The Hague, the Netherlands

⁷Pharmaceutics Division, College of Pharmacy, University of Texas in Austin, Austin, Texas 78712

⁸Institute of Pharmaceutical Technology, Goethe University, Frankfurt am Main, Germany

⁹RIVM—National Institute for Public Health and the Environment, Bilthoven, the Netherlands

Published online 11 October 2011 in Wiley Online Library (wileyonlinelibrary.com). DOI 10.1002/jps.22787

The original article to which this erratum refers was published in 2011;100:1618–1627.

In the original version of this article, there is an error in part (d) of the abstract. That error has been corrected below. We regret any confusion this may have caused.

Part (d) of the abstract conclusion should read: “and (d) if the test product contains sorbitol, sodium laurilsulfate, or propylene glycol, the test product needs to be qualitatively and quantitatively identical to its comparator with respect to these excipients.”